Trial reportDigestive diseases and sciences2008
Phase-II study of gemcitabine and cisplatin in patients with metastatic biliary and gallbladder cancer.
Trial report in Digestive diseases and sciences, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.
- Cisplatin/gemcitabine or oxaliplatin/gemcitabine in the treatment of advanced biliary tract cancer: a systematic review.Cancer medicine · 2014Pooled it
- Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan.British journal of cancer · 2010Trial
- Gemcitabine with carboplatin for advanced biliary tract cancers: a phase II single institution study.HPB : the official journal of the International Hepato Pancreato Biliary Association · 2010Trial
- Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial.British journal of cancer · 2010Trial
- Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study.British journal of cancer · 2008Trial
- Real-world efficacy and safety of nab-paclitaxel plus gemcitabine-cisplatin in patients with advanced biliary tract cancers: a multicenter retrospective analysis.Therapeutic advances in medical oncology · 2021Article
- miR-125b suppresses cellular proliferation by targeting c-FLIP in gallbladder carcinoma.Oncology letters · 2019Article
- The Effect and Mechanism of Vascular Endothelial Growth Factor (VEGF) on Tumor Angiogenesis in Gallbladder Carcinoma.Iranian journal of public health · 2019Article
- Comparison of FOLFIRINOX Chemotherapy with Other Regimens in Patients with Biliary Tract Cancers: a Retrospective Study.Journal of gastrointestinal cancer · 2017Article
- Signaling pathways as therapeutic targets in biliary tract cancer.Expert opinion on therapeutic targets · 2017Review
- Targeted therapy in biliary tract cancers-current limitations and potentials in the future.Journal of gastrointestinal oncology · 2017Review
- Gemcitabine Plus Cisplatin for Advanced Biliary Tract Cancer: A Systematic Review.Cancer research and treatment · 2015Review
- Identification of active chemotherapy regimens in advanced biliary tract carcinoma: a review of chemotherapy trials in the past two decades.Hepatic oncology · 2015Article
- Gallbladder Cancer in the 21st Century.Journal of oncology · 2015Review
- Chemotherapy and targeted therapy for gall bladder cancer.Indian journal of surgical oncology · 2014Review
- Chemotherapy for the biliary tract cancers: moving toward improved survival time.Journal of gastrointestinal cancer · 2012Review
- A successful treatment by hepatic arterial infusion therapy for advanced, unresectable biliary tract cancer.World journal of hepatology · 2010Article
- New insights on cholangiocarcinoma.World journal of gastrointestinal oncology · 2010Article
- Current management of gallbladder carcinoma.The oncologist · 2010Review
- Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990-2009.World journal of gastroenterology · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is no standard chemotherapy option for patients with biliary tract cancers. These patients present fairly ill and can have a rapid progression of disease. We conducted a multi-center, phase-II trial for patients with locally unresectable or metastatic bile duct or gallbladder adenocarcinomas using a modified regimen of gemcitabine and cisplatin to potentially improve tolerability. Patients received a 21-day treatment cycle of gemcitabine at 1,000 mg/m2 and cisplatin at 30 mg/m2 on days 1 and 8. To participate, 33 patients signed informed consent, and 30 patients received at least one dose of chemotherapy. By intention-to-treat analyses, 7 patients (21%) experienced a partial response and another 12 (36%) had stable disease for at least 12 weeks. The median progression-free survival was 6.3 months and median overall survival was 9.7 months. After 1 year, 39% of patients were alive. Most common grade 3-4 toxicities included neutropenia (33%), thrombocytopenia (23%), anemia (20%), nausea (20%), emesis (13%) and fatigue (10%). Of note, 52% of patients withdrew from study treatment, principally due to treatment-related adverse events. We concluded that this modified regimen appeared to have comparable activity to other gemcitabine and cisplatin regimens against advanced bile duct and gallbladder cancers, but there was still moderate toxicity in this patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.